Nearly $1 billion was spent from 2012 to 2021—practically all by the NIH—and the number of published papers on the topic increased 3.5-fold, but new drug approvals were scant.
Their shared pathogenic pathways explain why diagnoses correlated within five years of each other, as well as the dose-response correlation between the former and the latter.